Evidence map›Paper›PMID 34221871›Full record

ArticleActa pharmaceutica Sinica. B2021

Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An

Jiashu Xie, Zhengqiang Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. AssessingThe veterinary quarterly · 2024
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jiashu XieCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.
Zhengqiang WangCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Remdesivir (RDV) is the only US Food and Drug Administration (FDA)-approved drug for treating COVID-19. However, RDV can only be given by intravenous route, and there is a pressing medical need for oral antivirals. Significant evidence suggests that the role of the parent nucleoside GS-441524 in the clinical outcomes of RDV could be largely underestimated. We performed an

Indexed as

ADK, adenosine kinaseAntiviralCobi, cobicistatCOVID-19CYP, cytochrome P450DMPK, drug metabolism and pharmacokineticsDrug metabolismEMS, enhanced mass scanEPI, enhanced product ionFIPV, feline infectious peritonitis coronavirusGS-441524HINTs, histidine triad nucleotide binding proteinsHLMs, human liver microsomesIDA, information dependent acquisitionMLMs, mouse liver microsomesMRM, multiple reaction monitoringNucleosideOral bioavailabilityRdRp, RNA-dependent RNA-polymerasesRDV, remdesivirRemdesivirSARS-CoV-2SOF, sofosbuvirTAF, tenofovir alafenamide

Identifiers

PMID34221871
PMCPMC8245906

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.